TARX (Tarsier Pharma) Tax Provision: $0.00 Mil (TTM As of Dec. 2025)


What is Tarsier Pharma Tax Provision?

Tarsier Pharma TARX Tax Provision is $0.00 Mil as of Dec. 2025.

Tarsier Pharma's tax provision for the six months ended in Dec. 2025 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Tarsier Pharma Tax Provision Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma Tax Provision Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
Tax Provision
0.00 0.00 0.00

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Tax Provision 0.00 0.00 0.00 0.00 0.00

Tarsier Pharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $0.00 Mil mean?
Tarsier Pharma (TARX) has a Tax Provision of $0.00 Mil as of Dec. 2025. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's Tax Provision too high?
Tarsier Pharma's current Tax Provision is $0.00 Mil.
How does Tarsier Pharma's Tax Provision compare to ?
Tarsier Pharma's Tax Provision of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current Tax Provision is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current Tax Provision of $0.00 Mil. The current Tax Provision is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current Tax Provision is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.